TY - JOUR
T1 - Hematopoietic Stem Cell Transplantation for Multiple Myeloma
T2 - Guidelines from the American Society for Blood and Marrow Transplantation
AU - Shah, Nina
AU - Callander, Natalie
AU - Ganguly, Siddhartha
AU - Gul, Zartash
AU - Hamadani, Mehdi
AU - Costa, Luciano
AU - Sengsayadeth, Salyka
AU - Abidi, Muneer
AU - Hari, Parameswaran
AU - Mohty, Mohamad
AU - Chen, Yi Bin
AU - Koreth, John
AU - Landau, Heather
AU - Lazarus, Hillard
AU - Leather, Helen
AU - Majhail, Navneet
AU - Nath, Rajneesh
AU - Osman, Keren
AU - Perales, Miguel Angel
AU - Schriber, Jeffrey
AU - Shaughnessy, Paul
AU - Vesole, David
AU - Vij, Ravi
AU - Wingard, John
AU - Giralt, Sergio
AU - Savani, Bipin N.
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.
AB - Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.
KW - Guidelines
KW - Multiple myeloma
KW - Recommendations
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=84930577739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930577739&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2015.03.002
DO - 10.1016/j.bbmt.2015.03.002
M3 - Review article
C2 - 25769794
AN - SCOPUS:84930577739
VL - 21
SP - 1155
EP - 1166
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 7
ER -